Last reviewed · How we verify
FEMJA transplatation — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
FEMJA transplatation (FEMJA transplatation) — Hospices Civils de Lyon.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FEMJA transplatation TARGET | FEMJA transplatation | Hospices Civils de Lyon | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FEMJA transplatation CI watch — RSS
- FEMJA transplatation CI watch — Atom
- FEMJA transplatation CI watch — JSON
- FEMJA transplatation alone — RSS
Cite this brief
Drug Landscape (2026). FEMJA transplatation — Competitive Intelligence Brief. https://druglandscape.com/ci/femja-transplatation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing